CAMP4 Therapeutics Corporation Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
CAMP4 Therapeutics Corporation (CAMP) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 213.35 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-03-05
- CAMP4 Therapeutics Corporation share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 32.39K shares, a 198.54% increase year-over-year.
- CAMP4 Therapeutics Corporation share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 108.19K shares.
- CAMP4 Therapeutics Corporation share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-06-30 was 64.56K shares.
- CAMP4 Therapeutics Corporation share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-03-31 was 8.21K shares.
- CAMP4 Therapeutics Corporation share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 213.35K shares, a 108.72% increase from fiscal 2024.
- CAMP4 Therapeutics Corporation share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 102.22K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2025-12-31 | 32.39K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 140.58K shares derived: sum of 2 quarters · filed 2026-03-05 | 205.14K shares derived: sum of 3 quarters · filed 2026-03-05 | 213.35K shares 10-K · filed 2026-03-05 |
| 2025-09-30 | 108.19K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 172.75K shares derived: sum of 2 quarters · filed 2025-11-06 | 180.97K shares 10-Q · filed 2025-11-06 | 191.81K shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 64.56K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | 72.78K shares 10-Q · filed 2025-08-14 | 83.62K shares derived: sum of 3 quarters · filed 2025-08-14 | |
| 2025-03-31 | 8.21K shares 10-Q · filed 2025-05-13 | 19.06K shares derived: sum of 2 quarters · filed 2025-05-13 | ||
| 2024-12-31 | 10.85K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | 102.22K shares 10-K · filed 2025-03-27 | ||
| 2024-09-30 | 91.37K shares 10-Q · filed 2024-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |